Lipoproteins and metabolic control in hypertensive type II diabetics treated with clonidine
(1988) In Acta Medica Scandinavica 224(2). p.131-134- Abstract
- Twenty patients with type II diabetes mellitus and hypertension (WHO stages I and II) participated in a 3-month double-blind cross-over study to evaluate the effects of clonidine (75-300 micrograms daily) on blood pressure, glycemic control and plasma lipoproteins. Already after 1 month's treatment with clonidine the systolic and diastolic blood pressures had decreased, from 168/103 to 161/98 mmHg (p less than 0.01). Fasting blood glucose and HbA1c concentrations were unaffected by 3 months' treatment. Similarly, plasma lipid and lipoprotein concentrations remained unchanged throughout the study (i.e. mean high and low density lipoprotein cholesterol concentrations were 0.89 and 3.87 mmol/l on placebo vs. 0.90 and 3.98 mmol/l on... (More)
- Twenty patients with type II diabetes mellitus and hypertension (WHO stages I and II) participated in a 3-month double-blind cross-over study to evaluate the effects of clonidine (75-300 micrograms daily) on blood pressure, glycemic control and plasma lipoproteins. Already after 1 month's treatment with clonidine the systolic and diastolic blood pressures had decreased, from 168/103 to 161/98 mmHg (p less than 0.01). Fasting blood glucose and HbA1c concentrations were unaffected by 3 months' treatment. Similarly, plasma lipid and lipoprotein concentrations remained unchanged throughout the study (i.e. mean high and low density lipoprotein cholesterol concentrations were 0.89 and 3.87 mmol/l on placebo vs. 0.90 and 3.98 mmol/l on clonidine). Adverse effects were mild and tolerable, and consisted mainly of dryness of the mouth. We conclude that clonidine lowers the blood pressure in patients with type II diabetes without any adverse effects on glycemic control or plasma lipoproteins. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1104326
- author
- Nilsson-Ehle, Peter LU ; Ekberg, M ; Fridstrom, P ; Ursing, D and Lins, L E
- organization
- publishing date
- 1988
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Acta Medica Scandinavica
- volume
- 224
- issue
- 2
- pages
- 131 - 134
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:3048053
- scopus:0023810807
- ISSN
- 0001-6101
- language
- English
- LU publication?
- yes
- id
- 5990ed6f-ddde-46cc-ad70-9138258d6534 (old id 1104326)
- date added to LUP
- 2016-04-01 15:48:22
- date last changed
- 2021-01-03 09:29:25
@article{5990ed6f-ddde-46cc-ad70-9138258d6534,
abstract = {{Twenty patients with type II diabetes mellitus and hypertension (WHO stages I and II) participated in a 3-month double-blind cross-over study to evaluate the effects of clonidine (75-300 micrograms daily) on blood pressure, glycemic control and plasma lipoproteins. Already after 1 month's treatment with clonidine the systolic and diastolic blood pressures had decreased, from 168/103 to 161/98 mmHg (p less than 0.01). Fasting blood glucose and HbA1c concentrations were unaffected by 3 months' treatment. Similarly, plasma lipid and lipoprotein concentrations remained unchanged throughout the study (i.e. mean high and low density lipoprotein cholesterol concentrations were 0.89 and 3.87 mmol/l on placebo vs. 0.90 and 3.98 mmol/l on clonidine). Adverse effects were mild and tolerable, and consisted mainly of dryness of the mouth. We conclude that clonidine lowers the blood pressure in patients with type II diabetes without any adverse effects on glycemic control or plasma lipoproteins.}},
author = {{Nilsson-Ehle, Peter and Ekberg, M and Fridstrom, P and Ursing, D and Lins, L E}},
issn = {{0001-6101}},
language = {{eng}},
number = {{2}},
pages = {{131--134}},
publisher = {{Wiley-Blackwell}},
series = {{Acta Medica Scandinavica}},
title = {{Lipoproteins and metabolic control in hypertensive type II diabetics treated with clonidine}},
volume = {{224}},
year = {{1988}},
}